Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial ( HYBRID )
Cancer Medicine · 2024
DOI: 10.1002/cam4.7107 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Hiroyuki Arai und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Long‐term anti‐EGFR antibody treatment increases the risk of severe dermatologic toxicities. This single‐arm, phase II trial aimed to investigate the strategy of switching from cetuximab to bevacizumab in combination with FOLFIRI based on early tumor shrinkage (ETS) in patients with RAS wild‐type metastatic colorectal cancer (mCRC).
Methods
Radiologic assessment was performed to evaluate ETS, defined as ≥20% reduction in the sum of the largest diameters of target lesions 8 weeks after the introduction of FOLFIRI plus cetuximab. ETS‐negative patients switched to FOLFIRI plus bevacizumab, whereas ETS‐positive patients continued FOLFIRI plus cetuximab for eight more weeks, with a switch to FOLFIRI plus bevacizumab thereafter. The primary endpoint was progression‐free survival.
Results
This trial was prematurely terminated due to poor accrual after a total enrollment of 30 patients. In 29 eligible patients, 7 were ETS‐negative and 22 were ETS‐positive. Two ETS‐negative patients and 17 ETS‐positive patients switched to FOLFIRI plus bevacizumab 8 weeks and 16 weeks after initial FOLFIRI plus cetuximab, respectively. Median progression‐free and overall survival durations were 13.4 and 34.7 months, respectively. Six (20%) patients experienced grade ≥3 paronychia, which improved to grade ≤2 by 18 weeks. Grade ≥3 acneiform rash, dry skin, and pruritus were not observed in any patients.
Conclusions
Our novel treatment strategy delivered acceptable survival outcomes and reduced severe dermatologic toxicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
- Center for Hepato-Biliary-Pancreatic and Digestive Disease, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Japan.
- Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan.
- Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
- Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
- Department of Medical Oncology, Saku Central Hospital Advanced Care Center, Saku, Japan.
ORCID-Profile: Hiroyuki Arai, Hirokazu Shoji
Zitieren
APA
Arai, H., Tsuda, T., Sunakawa, Y., Shimokawa, M., Akiyoshi, K., Tokunaga, S., Shoji, H., Kunieda, K., Kotaka, M., Matsumoto, T., Nagata, Y., Mizukami, T., Mizuki, F., Danenberg, K. D., Boku, N., & Nakajima, T. E. (2024). Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial ( HYBRID ). Cancer Medicine. https://doi.org/10.1002/cam4.7107
Vancouver
Arai H, Tsuda T, Sunakawa Y, Shimokawa M, Akiyoshi K, Tokunaga S, et al. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial ( HYBRID ). Cancer Medicine. 2024. doi:10.1002/cam4.7107
BibTeX
@article{Arai2024,
author = {Arai, Hiroyuki and Tsuda, Takashi and Sunakawa, Yu and Shimokawa, Mototsugu and Akiyoshi, Kohei and Tokunaga, Shinya and Shoji, Hirokazu and Kunieda, Kenji and Kotaka, Masahito and Matsumoto, Toshihiko and Nagata, Yusuke and Mizukami, Takuro and Mizuki, Fumitaka and Danenberg, Kathleen D and Boku, Narikazu and Nakajima, Takako Eguchi},
title = {Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial ( HYBRID )},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7107}
}
EUVIMED